 Evoke Pharma, Inc. EVOK, a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal GI disorders and diseases, today announced that the U.S. Food and Drug Administration FDA has accepted the Companys resubmission of its 505b2 New Drug Application NDA for GimotiTM, the Companys nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis. 